What does Nureca do?

Nureca Ltd is an Indian micro-cap company specializing in home healthcare and wellness products, with net sales of 32 Cr and a net profit of 2 Cr for the quarter ending March 2025. It has a market cap of Rs 287 Cr and operates with a P/E ratio of 285.00.

Overview: <BR>Nureca Ltd is engaged in the business of home healthcare and wellness products within the healthcare services industry and operates as a micro-cap company.<BR><BR>History: <BR>Nureca Ltd was incorporated in India as Nureca Private Limited in 2016. It transitioned from a Private Limited Company to a Public Limited Company on 08 July 2020. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 32 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 287 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 285.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.22 <BR>Return on Equity: 0.44% <BR>Price to Book: 1.47<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Has Nureca declared dividend?

Nureca Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of February 24, 2022. However, the dividend yield is currently 0%, and the company has shown significant negative total returns over various periods.

Nureca Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 24 Feb 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -1.71%, the dividend return was 0%, resulting in a total return of -1.71%.<BR><BR>Over the past year, the price return was 8.92%, the dividend return was 0%, leading to a total return of 8.92%.<BR><BR>For the 2-year period, the price return was -26.2%, with a dividend return of 0%, resulting in a total return of -26.2%.<BR><BR>In the 3-year period, the price return was -73.96%, the dividend return was 0%, culminating in a total return of -73.96%.<BR><BR>Over the last 4 years, the price return was -81.2%, with a dividend return of 0.31%, resulting in a total return of -80.89%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Nureca Ltd has declared a dividend, the dividend yield is currently 0%, indicating that the company has not consistently provided dividends in recent periods. The total returns over various periods show significant volatility, particularly with negative returns in the longer terms.

Is Nureca overvalued or undervalued?

As of November 14, 2022, Nureca is considered overvalued with a high PE ratio of 287.01 and negative EV to EBIT and EBITDA ratios, leading to a valuation grade shift from very attractive to risky, despite a recent stock return of 5.53%.

As of 14 November 2022, the valuation grade for Nureca has moved from very attractive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as overvalued, primarily due to its exceptionally high PE ratio of 287.01 and negative EV to EBIT and EV to EBITDA ratios of -24.77 and -32.45, respectively. Additionally, the return on capital employed (ROCE) stands at -6.50%, further highlighting the challenges the company faces in generating returns.<BR><BR>In comparison to its peers, Nureca's valuation metrics are starkly higher; for instance, Poly Medicure Ltd. has a PE ratio of 66.7 and an EV to EBITDA of 47.56, while Vimta Labs Ltd. shows a PE of 34.32 and an EV to EBITDA of 18.35. These comparisons underscore Nureca's overvaluation relative to its industry. Despite a recent stock return of 5.53% over the past week, which outperformed the Sensex's 1.39%, the overall financial indicators suggest that Nureca's current market price of 283.50 is not justified by its underlying performance.

What is the technical trend for Nureca?

As of June 3, 2025, Nureca's technical trend is mildly bullish, supported by weekly MACD, KST, and Dow Theory indicators, despite some caution from daily moving averages and mixed signals from Bollinger Bands.

As of 3 June 2025, the technical trend for Nureca has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, supporting the positive outlook. The Dow Theory also aligns with this stance, indicating a mildly bullish trend on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, KST, and Dow Theory indicators.

When is the next results date for Nureca?

The next results date for Nureca is 15 July 2025.

The next results date for Nureca is scheduled for 15 July 2025.

Who are the peers of the Nureca?

Nureca's peers include Suraksha Diagno., 3B Blackbio, Sastasundar Ven., Prevest Denpro, One Global Serv, Hemant Surgical, Bilcare, Take Solutions, and Choksi Laborator. In terms of management risk, growth, and capital structure, Nureca ranks average among its peers, with a 1-year return of -5.31%.

Peers: The peers of Nureca are Suraksha Diagno., 3B Blackbio, Sastasundar Ven., Prevest Denpro, One Global Serv, Hemant Surgical, Bilcare, Take Solutions, and Choksi Laborator.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Hemant Surgical, while Average management risk is found at Suraksha Diagno., 3B Blackbio, Prevest Denpro, Nureca, and QMS Medical. Below Average management risk is noted at Sastasundar Ven., Bilcare, Take Solutions, and Choksi Laborator. Growth is Excellent at 3B Blackbio and One Global Serv, Good at Suraksha Diagno., Average at Choksi Laborator and Sastasundar Ven., and Below Average at Nureca, Prevest Denpro, Hemant Surgical, Bilcare, and Take Solutions. Capital Structure is Excellent at 3B Blackbio, One Global Serv, Prevest Denpro, Hemant Surgical, and Nureca, Good at Suraksha Diagno., and Below Average at Sastasundar Ven., Bilcare, Take Solutions, and Choksi Laborator.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 89.49%, while the lowest is Take Solutions at -52.91%. Nureca's own 1-year return is -5.31%, which is higher than Take Solutions but lower than most peers. Additionally, the six-month return is negative for One Global Serv, Bilcare, Take Solutions, and Nureca.

Who are in the management team of Nureca?

As of March 2023, the management team of Nureca includes Saurabh Goyal (Chairman & Managing Director), Aryan Goyal (Whole Time Director & CEO), and five independent directors: Vijay Kumar Sharma, Charu Singh, Ruchita Agarwal, Vikram Chaudhary, and Chetna Anand (Company Secretary & Compliance Officer). Each member contributes to the company's strategic direction and regulatory compliance.

As of March 2023, the management team of Nureca includes the following individuals:<BR><BR>1. Saurabh Goyal - Chairman & Managing Director<BR>2. Vijay Kumar Sharma - Independent Director<BR>3. Charu Singh - Independent Director<BR>4. Ruchita Agarwal - Independent Director<BR>5. Vikram Chaudhary - Independent Director<BR>6. Chetna Anand - Company Secretary & Compliance Officer<BR>7. Aryan Goyal - Whole Time Director & CEO<BR><BR>Each member plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the top shareholders of the Nureca?

The top shareholders of Nureca include promoter Saurabh Goyal with 31.86%, individual investors with 32.39%, and four Foreign Institutional Investors holding 1.07%. The highest public shareholder is Nisarg Vakharia at 1.78%, with no mutual funds currently invested.

The top shareholders of Nureca include the promoters, who hold a significant portion of the company's shares. The promoter with the highest holding is Saurabh Goyal, owning 31.86% of the shares. Additionally, individual investors collectively hold 32.39% of the shares. In terms of institutional investors, there are four Foreign Institutional Investors (FIIs) that hold a total of 1.07%. The highest public shareholder is Nisarg Vakharia, with a holding of 1.78%. There are no mutual funds currently holding shares in Nureca.

How big is Nureca?

As of 24th July, Nureca Ltd has a market capitalization of 252.00 Cr and reported net sales of 123.57 Cr with a net profit loss of 0.00 Cr over the latest four quarters.

As of 24th July, Nureca Ltd has a market capitalization of 252.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Nureca reported net sales of 123.57 Cr. The net profit for the same period was a loss of 0.00 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2025, with shareholder's funds amounting to 194.28 Cr and total assets of 206.50 Cr.

Are Nureca latest results good or bad?

Nureca's latest results show a strong sequential profit increase of 348.15% and a 21% year-on-year revenue growth, but concerns about sustainability arise due to over 50% of profit coming from non-operating income and a low return on equity of 0.44%. Investors should be cautious due to these operational challenges and the stock's 20% decline over the past year.

Nureca's latest results present a mixed picture. On one hand, the company reported a significant sequential increase in net profit, rising by 348.15% to ₹3.63 crore in Q2 FY26, which is a strong improvement compared to the previous quarter. Additionally, revenue grew by 21.00% year-on-year to ₹37.74 crore, indicating a recovery in demand.<BR><BR>However, there are serious concerns regarding the sustainability of this profitability. A substantial portion of the profit was driven by non-operating income, which accounted for over 50% of profit before tax. This reliance raises questions about the quality of earnings and the company's operational stability. Furthermore, Nureca's return on equity (ROE) is extremely low at just 0.44%, highlighting inefficiencies in generating returns for shareholders.<BR><BR>The technical indicators also suggest persistent bearish momentum, with the stock having lost nearly 20% of its value over the past year. Overall, while there are positive signs in terms of revenue growth and profit recovery, the underlying operational challenges and dependence on non-operating income cast doubt on the long-term outlook. Investors should proceed with caution, considering both the recent improvements and the significant risks involved.

How has been the historical performance of Nureca?

Nureca's historical performance has shown significant declines in net sales, operating profit, and profitability, with net sales dropping from 255.55 Cr in Mar'22 to 109.66 Cr in Mar'25, and operating profit turning negative by Mar'25. Despite slight increases in total assets and liabilities, the company has faced challenging financial conditions with negative cash flow from operating activities.

Answer:<BR>The historical performance of Nureca shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Nureca's net sales have varied considerably, peaking at 255.55 Cr in Mar'22 before declining to 109.66 Cr in Mar'25. The total operating income followed a similar trend, with a high of 255.55 Cr in Mar'22 and dropping to 109.66 Cr in Mar'25. The company's total expenditure, excluding depreciation, has also seen fluctuations, reaching a high of 200.04 Cr in Mar'22 and decreasing to 117.20 Cr in Mar'25. Operating profit, which was 63.21 Cr in Mar'22, turned negative in subsequent years, culminating in a loss of 7.54 Cr in Mar'25. Profit before tax showed a similar decline, moving from 60.98 Cr in Mar'22 to a modest profit of 1.34 Cr in Mar'25. The profit after tax also reflected this trend, with a significant drop from 44.96 Cr in Mar'22 to 0.85 Cr in Mar'25. The company's total assets increased slightly from 200.26 Cr in Mar'24 to 206.50 Cr in Mar'25, while total liabilities also rose from 200.26 Cr to 206.50 Cr in the same period. Cash flow from operating activities has been negative in recent years, with a notable outflow of 19.00 Cr in Mar'25. Overall, Nureca's financial performance indicates a challenging period with declining revenues and profitability, despite some stability in asset and liability levels.

Should I buy, sell or hold Nureca?

Which are the latest news on Nureca?

Why is Nureca falling/rising?

As of 03-Dec, Nureca Ltd's stock price is rising to 300.95, up 2.4%, driven by a 348.15% growth in net profit and consistent positive performance over the last three quarters. Increased promoter stake and strong trading volume further indicate robust market confidence in the company.

As of 03-Dec, Nureca Ltd's stock price is rising, currently at 300.95, reflecting a change of 7.05 or 2.4% increase. This upward movement can be attributed to several positive factors. Firstly, the company reported a remarkable growth in net profit of 348.15% in its latest results, which has contributed to positive investor sentiment. Additionally, Nureca has shown consistent performance, declaring positive results for the last three consecutive quarters, with net sales reaching their highest at Rs 37.74 crore.<BR><BR>Moreover, the stock has outperformed the sector by 2.64% today and opened with a gain of 3.64%. It also reached an intraday high of Rs 304.6. The trading volume indicates rising investor participation, with a delivery volume increase of 211.15% compared to the 5-day average. Furthermore, Nureca is trading above its moving averages across multiple time frames, indicating a strong bullish trend.<BR><BR>The confidence of promoters has also played a significant role, as they have increased their stake in the company by 0.64%, now holding 64.97%. This increase in stake is a positive signal regarding the future prospects of the business. Collectively, these factors contribute to the stock's rise, reflecting strong market confidence in Nureca Ltd.